Jul 28, 2026 04:01PM
Jul 28, 2026 04:01PM
Jul 22, 2026 04:01PM
Jul 22, 2026 04:01PM
Jun 23, 2026 04:01PM
Jun 23, 2026 04:01PM
Jun 17, 2026 07:31AM Verastem reports 86% six-month survival rate in pancreatic cancer trial
Jun 17, 2026 07:30AM
Jun 16, 2026 04:01PM
Jun 16, 2026 04:01PM
Jun 15, 2026 04:01PM
Jun 9, 2026 02:00PM
Jun 3, 2026 04:01PM
Jun 3, 2026 04:01PM Verastem Oncology Announces U.S. FDA Fast Track Designation for VS-7375, an Oral and Potential Best-in-Class Investigational KRAS G12D (ON/OFF) Inhibitor for the Treatment of KRAS G12D-Mutated Locally
May 8, 2026 07:30AM
May 7, 2026 04:01PM
Apr 30, 2026 07:30AM
Apr 10, 2026 07:00AM
Apr 10, 2026 07:00AM
Mar 17, 2026 06:03PM
Mar 17, 2026 04:44PM Verastem Oncology Announces Abstracts Accepted for Presentation on AVMAPKI™ FAKZYNJA™ (avutometinib capsules; defactinib tablets) Combination Therapy at the Society of Gynecologic Oncology 2026 An
Mar 4, 2026 04:01PM
Feb 4, 2026 07:31AM
Feb 4, 2026 07:30AM
Dec 29, 2025 04:01PM
Dec 29, 2025 04:01PM
Dec 15, 2025 04:01PM
Dec 15, 2025 04:01PM Verastem Oncology Announces Strategic Transition Plan to Accelerate Next Phase of Growth
Nov 14, 2025 12:41AM
Nov 14, 2025 12:41AM
Nov 13, 2025 04:07PM
Nov 13, 2025 04:07PM
Nov 4, 2025 07:30AM
Oct 23, 2025 04:01PM
Oct 23, 2025 04:01PM Verastem Oncology Announces Encouraging Preliminary Data from Ongoing Phase 1/2a Dose Escalation Trial of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in Patients with KRAS G12D Mutant Solid Tumors
Oct 19, 2025 04:15AM
Oct 19, 2025 04:15AM
Sep 11, 2025 08:18AM
Aug 13, 2025 04:29PM
Aug 13, 2025 04:29PM
Aug 7, 2025 04:05PM
Jul 24, 2025 07:30AM Verastem gets fast track status for pancreatic cancer drug VS-7375
Jul 24, 2025 07:30AM
Jul 11, 2025 04:12PM
Jul 11, 2025 04:12PM
Jul 8, 2025 08:50AM
Jun 30, 2025 04:02PM
Jun 30, 2025 04:02PM
Jun 24, 2025 04:02PM Verastem Oncology (VSTM) Announces First Patient Dosed with VS-7375 in U.S. Phase 1/2a Trial in KRAS G12D Advanced Solid Tumors
Jun 24, 2025 04:02PM

327,061 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All